Literature DB >> 19707176

Regulation of phosphodiesterase 3 in the pulmonary arteries during the perinatal period in sheep.

Bernadette Chen1, Satyan Lakshminrusimha, Lyubov Czech, Beezly S Groh, Sylvia F Gugino, James A Russell, Kathryn N Farrow, Robin H Steinhorn.   

Abstract

The role of cAMP in the pulmonary vasculature during the transition from intrauterine to extrauterine life is poorly understood. We hypothesized that cAMP levels are regulated by alterations in phosphodiesterase 3 (PDE3), which hydrolyzes cAMP. PDE3 protein expression and hydrolytic activity were increased in the resistance pulmonary arteries (PA) from spontaneously breathing 1-d-old (1dSB) lambs relative to equivalent-gestation fetuses. This was accompanied by a decrease in steady-state cAMP. Ventilation with 21% O2 and 100% O2 for 24 h disrupted the normal transition, whereas ventilation with 100% O2 + inhaled NO (iNO) for 24 h restored both PDE3 activity and cAMP to 1dSB levels. Consistent with these findings, relaxation to milrinone, a PDE3 inhibitor, was greater in the PA isolated from 1dSB and 100% O2 + iNO lambs, relative to fetal, 21% O2, and 100% O2 lambs. In conclusion, PDE3 expression and activity in the PA dramatically increase after birth, with a concomitant decrease in steady-state cAMP. Ventilation with either 21% O2 or 100% O2 blunts this PDE3 increase, whereas iNO restores PDE3 activity to levels equivalent to 1dSB lambs. The vasodilatory effects of milrinone were most pronounced in vessels from lambs with the highest PDE3 activity, i.e., 1dSB and 100% O2 + iNO lambs. Thus, milrinone may be most beneficial when used in conjunction with iNO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19707176      PMCID: PMC2796279          DOI: 10.1203/PDR.0b013e3181bce574

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  27 in total

1.  Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes.

Authors:  M C Walsh-Sukys; J E Tyson; L L Wright; C R Bauer; S B Korones; D K Stevenson; J Verter; B J Stoll; J A Lemons; L A Papile; S Shankaran; E F Donovan; W Oh; R A Ehrenkranz; A A Fanaroff
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

2.  Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries.

Authors:  K B Jourdan; N A Mason; L Long; P G Philips; M R Wilkins; N W Morrell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-06       Impact factor: 5.464

3.  Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery.

Authors:  O Pauvert; D Salvail; E Rousseau; C Lugnier; R Marthan; J P Savineau
Journal:  Biochem Pharmacol       Date:  2002-05-01       Impact factor: 5.858

6.  Breed differences in the duration of gestation in sheep.

Authors:  I D Smith
Journal:  Aust Vet J       Date:  1967-02       Impact factor: 1.281

7.  Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension.

Authors:  B Deb; K Bradford; R G Pearl
Journal:  Crit Care Med       Date:  2000-03       Impact factor: 7.598

8.  Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells.

Authors:  Kathryn N Farrow; Beezly S Groh; Paul T Schumacker; Satyan Lakshminrusimha; Lyubov Czech; Sylvia F Gugino; James A Russell; Robin H Steinhorn
Journal:  Circ Res       Date:  2007-11-08       Impact factor: 17.367

9.  Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn.

Authors:  Satyan Lakshminrusimha; Nicolas F M Porta; Kathryn N Farrow; Bernadette Chen; Sylvia F Gugino; Vasanth H Kumar; James A Russell; Robin H Steinhorn
Journal:  Pediatr Crit Care Med       Date:  2009-01       Impact factor: 3.624

10.  Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs.

Authors:  Stephan Thelitz; Peter Oishi; Lucienne S Sanchez; Janine M Bekker; Boaz Ovadia; Michael J Johengen; Stephen M Black; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2004-05       Impact factor: 3.624

View more
  12 in total

Review 1.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

Review 2.  Prenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheep.

Authors:  Demosthenes G Papamatheakis; Madalitso Chundu; Arlin B Blood; Sean M Wilson
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

Review 3.  Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

Authors:  Nicolas F M Porta; Robin H Steinhorn
Journal:  Clin Perinatol       Date:  2012-03       Impact factor: 3.430

Review 4.  Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension.

Authors:  Kathryn N Farrow; Robin H Steinhorn
Journal:  Handb Exp Pharmacol       Date:  2011

Review 5.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

Review 6.  Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Authors:  Satyan Lakshminrusimha; Bobby Mathew; Corinne L Leach
Journal:  Semin Perinatol       Date:  2016-01-14       Impact factor: 3.300

Review 7.  Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates.

Authors:  S Lakshminrusimha; G G Konduri; R H Steinhorn
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

8.  Diagnosis and treatment of pulmonary hypertension in infancy.

Authors:  Robin H Steinhorn
Journal:  Early Hum Dev       Date:  2013-09-29       Impact factor: 2.079

Review 9.  The pulmonary circulation in neonatal respiratory failure.

Authors:  Satyan Lakshminrusimha
Journal:  Clin Perinatol       Date:  2012-09       Impact factor: 3.430

10.  Persistent pulmonary hypertension of the newborn.

Authors:  Vinay Sharma; Sara Berkelhamer; Satyan Lakshminrusimha
Journal:  Matern Health Neonatol Perinatol       Date:  2015-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.